Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
04/26/04	SEK 0.8230	-3.18%	9,39,919
03/26/03	SEK 0.8500	-0.35%	6,66,382
02/26/02	SEK 0.8530	+5.57%	14,11,147
01/26/01	SEK 0.8080	+1.00%	7,07,328
31/26/31	SEK 0.8000	-4.76%	6,80,209

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 09:30:00 04/09/2026 pm IST			5-day change	1st Jan Change
0.8230 ^SEK	-3.18%		-2.02%	-0.72%

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	17Cr 1.74Cr 1.5Cr 1.41Cr 1.29Cr 2.41Cr 164.59Cr 2.42Cr 6.47Cr 84Cr 6.55Cr 6.4Cr 272.04Cr	P/E 2026 *	-3.05x	P/E 2027 *	-2.17x
Enterprise Value	15Cr 1.58Cr 1.36Cr 1.28Cr 1.17Cr 2.18Cr 148.8Cr 2.19Cr 5.85Cr 76Cr 5.92Cr 5.79Cr 245.94Cr	EV / Sales 2026 *	4.81x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
CBOE		Real-time
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW
24/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
24/06	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
12/06	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
08/06	Alzinova raises SEK 15.2 million before issuance costs	FW
26/05	Calendar Tuesday May 26	FW
25/05	Calendar Tuesday May 26	FW
21/05	Alzinova secures 80 percent of TO4 warrants	FW

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation : Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations : Alzinova AB

Press Releases : Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors : Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ
20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
20/08	Alzinova publishes interim report for the period January - June 2026	AQ
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ

1 day	-3.18%
1 week	-2.02%
Current month	+2.88%
1 month	-19.94%
3 months	+84.53%
6 months	+39.26%
Current year	-0.72%

1 week	0.77	0.86
1 month	0.75	1.14
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-3.18%	-2.02%	-42.21%	-73.75%	1.74Cr
LONZA GROUP AG	-2.54%	-2.84%	-1.77%	+14.72%	4.89TCr
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+523.39%	4.5TCr
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+21.22%	4.41TCr
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+74.90%	4.07TCr
CELLTRION, INC.	+0.53%	-1.36%	+16.87%	+47.12%	3.35TCr
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	1.78TCr
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+123.04%	1.65TCr
EUROFINS SCIENTIFIC SE	-1.01%	+0.50%	+13.91%	+31.45%	1.47TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.22%	1.38TCr
Average	-1.15%	+0.28%	+61.13%	+89.26%	2.75TCr
Weighted average by Cap.	-1.03%	+0.11%	+89.41%	+127.92%

	2026 *	2027 *
Net sales	3.14Cr 32.77L 28.2L 26.53L 24.24L 45.34L 31Cr 45.46L 1.22Cr 16Cr 1.23Cr 1.2Cr 51Cr	-
Net income	-44.5L -5L -4L -4L -3L -6L -4.39Cr -6L -17.27L -2.25Cr -17.47L -17.09L -7.26Cr	-7.7Cr -80.49L -69.26L -65.16L -59.53L -1.11Cr -76Cr -1.12Cr -2.99Cr -39Cr -3.02Cr -2.96Cr -125.6Cr
Net Debt	-1.6Cr -16.72L -14.39L -13.54L -12.37L -23.14L -16Cr -23.2L -62.09L -8.1Cr -62.8L -61.43L -26Cr	-1.9Cr -19.86L -17.09L -16.08L -14.69L -27.48L -19Cr -27.55L -73.73L -9.62Cr -74.58L -72.95L -31Cr